Positrons Emission Tomography (PET) using 18FDG and occult diseases in cancerology: The experiment of the René Huguenin Center;Tomographie d'émission de positrons (TEP) au 18FDG et maladie occulte en cancérologie: l'Expérience du centre René Huguenin

Immuno-Analyse et Biologie Specialisee

Volumn 19, Issue 5 SPEC. ISS., 2004, Pages 269-273

  Pecking, A P ^a   Corone Mechelany C ^a   Alberini J L ^a   Gutman, F ^a   Sarandi, F ^a   Bertrand Kermorgant, F ^a   Pallud, C ^a   Floiras, J L ^a   Goupil, A ^b   Pichon, M F ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b Serv d'Oncol Med Ctr Rene H   (France)

Author keywords

18FDG; Maladie occulte; Marqueurs tumoraux; Occult disease; Tumour markers

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CAMERA; CANCER; CANCER PATIENT; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; METASTASIS; OVARY CANCER; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STANDARD;

EID: 4744366249     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2004.07.006     Document Type: Article

References (25)

1. H. Abdel Nabi, and R. Doerr Clinical applications of indium 111-labelled monoclonal antibody imaging in colorectal cancer patients Semin. Nucl. Med. XXIII 1993 99 105
2. American Society of Clinical Oncology Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer J. Clin. Oncol. 14 1996 2843 2877 update 2001; 19: 1865-1878
3. G. Beets, F. Penninckx, C. Schiepers, L. Filez, L. Mortelmans, and R. Kerremans Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer Br. J. Surg. 81 1994 1666 1670
4. E. Boren Jr., D. Delbeke, J. Patton, and M. Sandler Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies Eur. J. Nucl. Med. 26 1999 379 387
5. Breast Specialty Croup of the British Association of Surgical Oncology The guidelines for the management of metastatic bone disease in breast cancer in the United Kingdom Eur. J. Surg. Oncol. 25 1999 3 23
6. B. Cantwell, J. Fennelly, and M. Jones Evaluation of follow-up methods to detect relapse mastectomy in breast cancer patients Ir. J. Med. Sc. 151 1982 1 5
7. O. De Dreuille, D. Brasse, B. Bendriem, C. Corone, O. Lamer, and J. Gaillard Détection en coïncidence sur gammacaméra conventionnelle: principes et performances Med. Nucl. 23 1999 81 92
8. D. Delbeke, J. Patton, W. Martin, and M. Sandler FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders J. Nucl. Med. 40 1999 110 117
9. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy Lancet 1 1992 1 15 71-85
10. F. Flanagan, F. Dehdashti, O. Ogunbiyi, I. Kodner, and B. Siegel Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer Ann. Surg. 227 1998 319 323
11. J. Geraghty, E. Coveney, F. Sherry, N. O'Higgins, and M. Duffy CAI5.3 in patients with locoregional and metastatic breast carcinome Cancer 70 1992 2831 2834
12. M. Gion Serum markers in breast cancer management Breast 1 1992 173 178
13. D. Goldenberg Monoclonal antibodies in cancer detection and therapy Am. J. Med. 94 1993 297 303
14. A. Maldonado, F. Sancho, J. Cerdan, A. Lozano, N. Mohedano, and J. Jimenez FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA Level. Experience in 72 Patients Clin. Positron Imaging 3 2000 170 172
15. R. Molina, G. Zanôn, X. Filella, F. Moreno, J. Jo, and M. Daniels Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients Breast Cancer Res. Treat. 36 1995 41 48
16. D. Palli, A. Russo, C. Saieva, S. Ciatto, M. Rosselli Del Turco, and V. Distante Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial JAMA 281 1999 1586 1594
17. A. Pecking, C. Mechelany-Corone, and M. Pichon 1959-1999: from serum markers to 18-FDG in oncology. The experience of the Rene-Huguenin Center Pathol. Biol. 48 2000 819 824
18. A. Pecking, C. Méchélany-Corone, F. Bertrand-Kermorgant, J. Albérini, A. Goupil, and J. Floiras Detection of occult disease in breast cancer using Fluorodeoxyglucose camera based positron emission tomography Clin. Breast Cancer 2 2001 229 234
19. A. Pecking, C. Méchélany-Corone C.*Albérini, F. Bertrand-Kermorgant, C. Pallud, and M. Pichon La tomographie d'émission par positron au 18 fluorodeoxyglucose (TEP-FDG) dans les cancers épithéliaux de l'ovaire Oncologie 3 2001 145 149
20. P. Shreve, R. Stevenson, E. Deters, P. Kison, M. Gross, and R. Wahl Oncologic diagnosis with 2-(fluorine-18)Fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner Radiology 207 1998 431 437
21. L. Strauss, and P. Conti The application of PET in Clinical Oncology J. Nucl. Med. 32 1991 623 648
22. The GIVIO Investigators Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomised controlled trial JAMA 271 1994 1587 1592
23. A. Van Dalen New markers for breast carcinoma-associated antigen in comparison with CAI5.3 Anticancer Res. 16 1996 2339 2343
24. R. Wahl, R. Cody, and G. Hutchins Positron Emission Tomographic scanning of primary and metastatic breast with the radiolabeld glucose analog New Eng. J. Med. 1991 200 324
25. P. Willkomm, H. Bender, M. Bangard, P. Decker, F. Grunwald, and H. Biersack FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma J. Nucl. Med. 41 2000 1657 1663